Tactical Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Phase 1
Active, not recruiting
- Conditions
- Solid Tumors, Glioblastoma, Recurrent Malignant Gliomas
- Interventions
- Drug: CTODrug: CTO, Temodar®, Radiation therapyDrug: CTO and Temodar®
- First Posted Date
- 2010-04-21
- Last Posted Date
- 2024-07-09
- Lead Sponsor
- Tactical Therapeutics, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT01107522
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸New York University, New York, New York, United States
🇺🇸Oregon Health and Sciences University, Portland, Oregon, United States
© Copyright 2025. All Rights Reserved by MedPath